journal
MENU ▼
Read by QxMD icon Read
search

Annals of the Rheumatic Diseases

journal
https://www.readbyqxmd.com/read/30242033/prevalence-and-incidence-of-psoriasis-and-psoriatic-arthritis
#1
Philipp Sewerin, Ralph Brinks, Matthias Schneider, Isabell Haase, Stefan Vordenbäumen
No abstract text is available yet for this article.
September 21, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30242032/evaluation-of-retinal-microvascular-density-in-patients-affected-by-systemic-lupus-erythematosus-an-optical-coherence-tomography-angiography-study
#2
Paola Conigliaro, Massimo Cesareo, Maria Sole Chimenti, Paola Triggianese, Claudia Canofari, Gianluca Aloe, Carlo Nucci, Roberto Perricone
No abstract text is available yet for this article.
September 21, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30242031/immune-checkpoint-inhibitor-rechallenge-in-patients-with-immune-related-myositis
#3
Julie Delyon, Florence Brunet-Possenti, Sarah Leonard-Louis, Dimitri Arangalage, Mathilde Baudet, Barouyr Baroudjian, Celeste Lebbe, Baptiste Hervier
No abstract text is available yet for this article.
September 21, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30242030/coffee-consumption-and-gout-a-mendelian-randomisation-study
#4
Young Ho Lee
No abstract text is available yet for this article.
September 21, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30237203/can-disease-activity-in-patients-with-psoriatic-arthritis-be-adequately-assessed-by-a-modified-disease-activity-index-for-psoriatic-arthritis-dapsa-based-on-28-joints
#5
Brigitte Michelsen, Joseph Sexton, Josef S Smolen, Daniel Aletaha, Niels Steen Krogh, Désirée van der Heijde, Tore K Kvien, Merete Lund Hetland
OBJECTIVE: To test the psychometric performance of a modified Disease Activity index for PSoriatic Arthritis (DAPSA) using 28 instead of 66 swollen/68 tender joint counts (SJC/TJC). METHODS: We included patients with psoriatic arthritis (PsA) from the Danish national quality registry DANBIO, divided into examination (n=3157 patients, 23987 visits) and validation cohorts (n=3154 patients, 24160 visits). We defined DAPSA28 = (28TJC × conversion factor1 ) + (28SJC × conversion factor2 ) + patient global (0-10VAS) + pain (0-10VAS) + C reactive protein (CRP) (mg/dL)...
September 20, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30232194/two-distinct-clinical-phenotypes-of-pulmonary-arterial-hypertension-secondary-to-systemic-lupus-erythematosus
#6
Fangfang Sun, Yunxia Lei, Wanlong Wu, Li Guo, Kaiwen Wang, Zhiwei Chen, Wenwen Xu, Xiaodong Wang, Ting Li, Xiao Zhang, Shuang Ye
No abstract text is available yet for this article.
September 19, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30232193/significant-joint-destructive-association-of-hla-drb1-04-05-independent-of-das28-in-rheumatoid-arthritis
#7
Hideaki Tsuji, Katsunori Ikari, Koichiro Ohmura, Koichiro Yano, Moritoshi Furu, Motomu Hashimoto, Hiromu Ito, Takao Fujii, Wataru Yamamoto, Atsuo Taniguchi, Hisashi Yamanaka, Tsuneyo Mimori, Chikashi Terao
No abstract text is available yet for this article.
September 19, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30232192/clinical-trials-in-children-and-adolescents-with-systemic-lupus-erythematosus-methodological-aspects-regulatory-landscape-and-future-opportunities
#8
Hermine I Brunner, Alberto Martini, Daniel J Lovell, Nicolino Ruperto
Childhood-onset systemic lupus erythematosus (cSLE) is rare in many regions of the world, including Europe. Access to approved medications for cSLE is currently limited, among others, due to a lack of high-quality evidence from clinical trials. The objectives of the study were to evaluate the current regulatory framework regarding medication approvals, delineate barriers to clinical trial conduct, and strategies to improve access to new medications for cSLE. Relevant methodological and regulatory aspects, epidemiological data, study designs and outcome measures are reviewed, and the results of a survey among Paediatric Rheumatology International Trials Organisation/Pediatric Rheumatology Collaborative Study Group investigators are presented...
September 19, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30209031/increased-autophagy-is-cytoprotective-against-podocyte-injury-induced-by-antibody-and-interferon-%C3%AE-in-lupus-nephritis
#9
Yuan-Yuan Qi, Xu-Jie Zhou, Fa-Juan Cheng, Ping Hou, Ya-Li Ren, Su-Xia Wang, Ming-Hui Zhao, Li Yang, Jennifer Martinez, Hong Zhang
OBJECTIVE: More recent studies suggested that defects in autophagy contribute to the pathogenesis of SLE, especially in adaptive immunity. Occurrence and progression of lupus nephritis (LN) is the end result of complex interactions between regulation of immune responses and pathological process by renal resident cells, but there is still a lot of missing information for an establishment on the role of autophagy in pathogenesis of LN and as a therapy target. METHODS: Systemic and organ-specific aetiologies of autophagy were first evaluated by autophagy protein quantification in tissue homogenates in MRL lpr/lpr lupus prone and female C57BL mice...
September 12, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30194275/dose-reduction-of-baricitinib-in-patients-with-rheumatoid-arthritis-achieving-sustained-disease-control-results-of-a-prospective-study
#10
Tsutomu Takeuchi, Mark C Genovese, Boulos Haraoui, Zhanguo Li, Li Xie, Rena Klar, Ana Pinto-Correia, Susan Otawa, Pedro Lopez-Romero, Inmaculada de la Torre, William Macias, Terence P Rooney, Josef S Smolen
OBJECTIVES: This study investigated the effects of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once a day. METHODS: Patients who completed a baricitinib phase 3 study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥15 months and maintained CDAI low disease activity (LDA) or remission (REM) were blindly randomised to continue 4 mg or taper to 2 mg...
September 7, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30194274/will-spar-be-useful-in-the-usual-patients-with-scleroderma
#11
Arghya Chattopadhyay, Varun Dhir, Shefali Sharma, Aman Sharma, Sanjay Jain
No abstract text is available yet for this article.
September 7, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30194273/characteristics-of-difficult-to-treat-rheumatoid-arthritis-results-of-an-international-survey
#12
Nadia M T Roodenrijs, Maria J H de Hair, Marlies C van der Goes, Johannes W G Jacobs, Paco M J Welsing, Désirée van der Heijde, Daniel Aletaha, Maxime Dougados, Kimme L Hyrich, Iain B McInnes, Ulf Mueller-Ladner, Ladislav Senolt, Zoltan Szekanecz, Jacob M van Laar, György Nagy
OBJECTIVES: Patients with difficult-to-treat rheumatoid arthritis (RA) remain symptomatic despite treatment according to current European League Against Rheumatism (EULAR) management recommendations. These focus on early phases of the disease and pharmacological management. We aimed to identify characteristics of difficult-to-treat RA and issues to be addressed in its workup and management that are not covered by current management recommendations. METHODS: An international survey was conducted among rheumatologists with multiple-choice questions on disease characteristics of difficult-to-treat RA...
September 7, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30185417/galectin-9-is-an-easy-to-measure-biomarker-for-the-interferon-signature-in-systemic-lupus-erythematosus-and-antiphospholipid-syndrome
#13
Lucas L van den Hoogen, Joël A G van Roon, Jorre S Mertens, Judith Wienke, Ana Pinheiro Lopes, Wilco de Jager, Marzia Rossato, Aridaman Pandit, Catharina G K Wichers, Femke van Wijk, Ruth D E Fritsch-Stork, Timothy R D J Radstake
OBJECTIVE: The interferon (IFN) signature is related to disease activity and vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and represents a promising therapeutic target. Quantification of the IFN signature is currently performed by gene expression analysis, limiting its current applicability in clinical practice. Therefore, the objective of this study was to establish an easy to measure biomarker for the IFN signature. METHODS: Serum levels of galectin-9, CXCL-10 (IP-10) and tumour necrosis factor receptor type II (TNF-RII) were measured in patients with SLE, SLE+APS and primary APS (PAPS) and healthy controls (n=148) after an initial screening of serum analytes in a smaller cohort (n=43)...
September 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30185416/response-to-the-revised-2017-international-consensus-on-anca-testing-in-small-vessel-vasculitis-support-from-an-external-quality-assessment-by-broeders-et-al
#14
Jan Damoiseaux
No abstract text is available yet for this article.
September 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30185415/pre-existing-antiacetylcholine-receptor-autoantibodies-and-b-cell-lymphopaenia-are-associated-with-the-development-of-myositis-in-patients-with-thymoma-treated-with-avelumab-an-immune-checkpoint-inhibitor-targeting-programmed-death-ligand-1
#15
Andrew L Mammen, Arun Rajan, Katherine Pak, Tanya Lehky, Livia Casciola-Rosen, Renee N Donahue, Lauren M Lepone, Anastasia Zekeridou, Sean J Pittock, Raffit Hassan, Jeffrey Schlom, James L Gulley
No abstract text is available yet for this article.
September 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30185414/chronic-hydroxychloroquine-chloroquine-exposure-for-connective-tissue-diseases-and-risk-of-alzheimer-s-disease-a-population-based-cohort-study
#16
Laurence Fardet, Irwin Nazareth, Irene Petersen
No abstract text is available yet for this article.
September 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30185413/revised-2017-international-consensus-on-anca-testing-in-small-vessel-vasculitis-support-from-an-external-quality-assessment
#17
Sylvia Broeders, Sylvie Goletti, Jean-Paul Tomasi, Carolien Bonroy, René-Louis Humbel, Laurence Lutteri, Sofie Schouwers, Lieve Van Hoovels, Martine Vercammen, Xavier Bossuyt
No abstract text is available yet for this article.
September 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30158123/adding-baseline-protein-biomarkers-to-clinical-predictors-does-not-enhance-prediction-of-treatment-response-to-a-methotrexate-strategy-in-early-rheumatoid-arthritis
#18
Xavier M Teitsma, Johannes W G Jacobs, Pascal H P de Jong, Johanna M W Hazes, Angelique E A M Weel, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Johannes W J Bijlsma, Floris P J G Lafeber
No abstract text is available yet for this article.
August 29, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30158122/how-to-reduce-the-waiting-time-for-the-first-consultation-with-the-rheumatologist-as-a-first-step-for-a-timely-treatment
#19
Omar Valenzuela, Sebastián E Ibáñez Vodnizza
No abstract text is available yet for this article.
August 29, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/30154088/deep-phenotyping-of-osteoarthritis-a-step-forward
#20
EDITORIAL
Francis Berenbaum
No abstract text is available yet for this article.
August 28, 2018: Annals of the Rheumatic Diseases
journal
journal
20039
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"